Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026 and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “Arcus is entering a new era, with a clear path for casdatif.

Business Wire • May 5, 2026

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.14 per share a year ago.

Zacks Investment Research • May 5, 2026

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 28, 2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 4,200 shares of the Company's common stock at an exercise price per share of $25.13, which was the.

Business Wire • Apr 24, 2026

What's Going On With Arcus Biosciences Stock On Wednesday?

Cancer-focused biotech, Arcus Biosciences, Inc. (NYSE:RCUS) stock is trading higher on Wednesday after the company's stock closed lower on Tuesday following a lung cancer trial update.

Benzinga • Apr 22, 2026

Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?

Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • Apr 22, 2026

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Tuesday, May 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline updates for the quarter ended March 31st, 2026. In.

Business Wire • Apr 21, 2026

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.

24/7 Wall Street • Apr 1, 2026

Arcus Biosciences: Q4 Beat And Casdatifan's Story So Far

Arcus Biosciences posted strong FY25 results, beating EPS and revenue estimates despite no commercial products and heavy R&D investment. RCUS's valuation premium is driven by Casdatifan, a next-generation HIF-2α inhibitor showing superior efficacy and safety versus competitors in ccRCC. The company's $1.01B cash position funds operations into at least 2H28, supporting multiple Phase 3 programs and mitigating near-term financing risk.

Seeking Alpha • Mar 3, 2026